Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

• Published in: Haematologica (Roma) Vol. 107; no. 3; pp. 625 - 634
• Main Authors: Benjamini, Ohad, Rokach, Lior, Itchaki, Gilad, Braester, Andrei, Shvidel, Lev, Goldschmidt, Neta, Shapira, Shirley, Dally, Najib, Avigdor, Abraham, Rahav, Galia, Lustig, Yaniv, Ben David, Shirley Shapiro, Fineman, Riva, Paz, Alona, Bairey, Osnat, Polliack, Aaron, Levy, Ilana, Tadmor, Tamar
• Format: Journal Article
• Language: English
• Published: Italy Fondazione Ferrata Storti 01.03.2022; Ferrata Storti Foundation
• Subjects: Antibodies, Viral; BNT162 Vaccine; COVID-19 - prevention & control; COVID-19 Vaccines - adverse effects; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; RNA, Messenger - genetics; SARS-CoV-2

Patients with chronic lymphocytic leukemia (CLL) have a suboptimal humoral response to vaccination. Recently, BNT162b2, an mRNA COVID-19 vaccine with a high efficacy of 95% in immunocompetent individuals, was introduced. We investigated the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine i...